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Background
Melanoma is the most serious form of skin cancer
because of its increasing incidence. Recent studies
demonstrated the involvement of specific microRNAs in
the melanoma initiation, progression, diagnosis and
prognosis. Currently the treatment for metastatic mela-
noma with the mutation of BRAF V600E expects the
Vemurafenib that blocks mutated BRAF protein leading
to cell-cycle arrest. Unfortunately, the reactivation of
MAPK signalling or activation of an alternative signal-
ling pathway, as PI3K/AKT/mTOR, deriving from differ-
ent mechanisms of acquired tumor drug resistance (as
secondary mutations in NRAS or MEK1) causes disease
progression within 6–8 months after the therapy begin-
ning. The aim of this work was to evaluate a possible
MAPK reactivation due to microRNAs involvement or
to unclassified gene variants not yet associated to meta-
static melanoma therapy response.
Materials and methods
A set of 43 patients, treatment naïve and with confirmed
histological stage IV of metastatic melanoma was enrolled
through the Oncology Unit of the IRCCS “Giovanni Paolo
II” in Bari, Italy. Thirty melanoma cases were BRAF
mutated at the codon 600, while 13 were wild type. We
analyzed 15 microRNAs and the correspondent target
genes by TaqMan probes. Moreover we developed an
Ampliseq Custom panel for ION Torrent PGM Sequencer
to analyze the coding region of several target genes with a
coverage of 93.85%. The correlation between microRNA
expression signature and the detected mutations with time
to progression of patients treated with Vemurafenib has
been analyzed.
Results
High expression of miR-192 and miR-193b* and low
expression of miR-132 resulted associated with short time
to progression, by the Kaplan-Meier survival curves, indi-
cating a poor prognosis. MiR-193b*was also included in
the results of the multivariate Cox analysis that revealed a
significant signature of 11 microRNAs (miR-34a, miR-
146b, miR-182, miR-155, miR-101, miR-222, miR-21,
miR-338-3p, miR-193b*, miR-193a and miR-191) whose
high expression was associated to worse prognosis. The
univariate Cox model confirms that potential role for
miR-193b* as poor outcome marker. Moreover we
detected mutations associated with the response to differ-
ent therapeutic approach and, more interestingly, we iden-
tified gene alterations not yet associated to this pathology.
Conclusions
Our study highlighted the prognostic role of microRNAs
in metastatic melanoma. Furthermore the use of Next
Generation Sequencing to detect known or novel muta-
tions could be useful in clinical practice.
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